Crispr Therapeutics AG (CRSP)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $4.10B
Last updated: Nov 17, 2026 at 11:05 AM ET
Crispr Therapeutics AG (CRSP) Financials: Revenue, Profit and Cash Flow
Crispr Therapeutics AG reported revenue of $3.51M for the fiscal year ended Dec 31, 2025, down 90.6% from the year before. That year, net income was -$581.60M with a net margin of -16569.8%, operating cash flow was -$345.01M and free cash flow was -$345.93M. The quarter ended Sep 30, 2026 had revenue of $12.67M and net income of -$111.44M.
Revenue and Margins
Over the 9 years to Dec 2025, revenue fell from $5.16M, a compound annual decline of 4.2%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $3.51M | -90.6% | 100.0% | -18933.6% | -16569.8% |
| Dec 2024 | $37.31M | -89.9% | 100.0% | -1250.4% | -981.5% |
| Dec 2023 | $371.21M | +30885.5% | 100.0% | -60.0% | -41.4% |
| Dec 2022 | $1.20M | -99.9% | 100.0% | -56190.4% | -54271.7% |
| Dec 2021 | $914.96M | +127154.9% | 100.0% | 40.8% | 41.3% |
| Dec 2020 | $719.00K | -99.8% | 100.0% | -49295.5% | -48520.9% |
| Dec 2019 | $289.59M | +9169.8% | 100.0% | 16.1% | 23.1% |
| Dec 2018 | $3.12M | -92.4% | 100.0% | -5087.8% | -5281.1% |
| Dec 2017 | $41.00M | +693.9% | 100.0% | -157.7% | -166.7% |
| Dec 2016 | $5.16M | N/A | 100.0% | -1319.3% | -449.3% |
Income Statement
In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.51M | $37.31M | $371.21M | $1.20M | $914.96M | $719.00K | $289.59M | $3.12M | $41.00M | $5.16M |
| Gross profit | $3.51M | $37.31M | $371.21M | $1.20M | $914.96M | $719.00K | $289.59M | $3.12M | $41.00M | $5.16M |
| Research and development | $381.06M | $310.24M | $387.33M | $461.64M | $340.57M | $221.38M | $179.36M | $113.77M | $69.80M | $42.24M |
| Operating income | -$664.57M | -$466.57M | -$222.54M | -$673.16M | $373.53M | -$354.44M | $46.74M | -$158.94M | -$64.65M | -$68.13M |
| Net income | -$581.60M | -$366.25M | -$153.61M | -$650.17M | $377.66M | -$348.87M | $66.86M | -$164.98M | -$68.36M | -$23.20M |
| EBITDA | -$558.49M | -$343.41M | -$130.88M | -$626.33M | $397.48M | -$338.87M | $77.50M | -$156.63M | -$61.82M | $11.31M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $12.67M | $10.18M | $1.46M | $864.00K | $889.00K | $892.00K | $865.00K | $35.69M | $602.00K | $517.00K | $504.00K | $201.21M |
| Gross profit | $12.67M | $10.18M | $1.46M | $864.00K | $889.00K | $892.00K | $865.00K | $35.69M | $602.00K | $517.00K | $504.00K | $201.21M |
| Operating income | -$130.04M | -$117.27M | -$130.25M | -$154.76M | -$132.06M | -$229.32M | -$148.42M | -$64.59M | -$110.13M | -$151.26M | -$140.59M | $69.58M |
| Net income | -$111.44M | -$91.15M | -$122.93M | -$130.61M | -$106.44M | -$208.55M | -$136.00M | -$37.31M | -$85.94M | -$126.41M | -$116.59M | $89.35M |
Balance Sheet
As of Dec 2025, cash and equivalents exceeded total debt of $18.58M by $328.98M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $2.27B | $2.24B | $2.23B | $2.24B | $2.75B | $1.83B | $1.07B | $489.02M | $271.35M | $344.96M |
| Current assets | $1.99B | $1.94B | $1.91B | $1.85B | $2.42B | $1.72B | $987.55M | $466.39M | $248.38M | $320.19M |
| Cash and equivalents | $347.56M | $298.26M | $389.48M | $211.88M | $923.03M | $1.17B | $943.77M | $456.65M | $239.76M | $315.52M |
| Total liabilities | $343.43M | $309.95M | $346.77M | $367.58M | $352.42M | $163.73M | $127.33M | $96.82M | $83.51M | $112.12M |
| Short-term debt | $18.58M | $17.29M | $15.63M | $15.84M | $12.16M | $11.36M | $8.49M | $35.32M | $44.19M | $60.28M |
| Shareholder equity | $1.92B | $1.93B | $1.88B | $1.88B | $2.40B | $1.66B | $939.42M | $392.19M | $187.83M | $232.85M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $2.56B | $2.65B | $2.73B | $2.27B | $2.25B | $2.03B | $2.17B | $2.24B | $2.26B | $2.34B | $2.44B | $2.23B |
| Total liabilities | $908.34M | $904.22M | $911.26M | $343.43M | $329.33M | $318.59M | $336.94M | $309.95M | $316.47M | $358.90M | $355.08M | $346.77M |
| Cash and equivalents | $192.03M | $291.34M | $423.31M | $355.19M | $286.50M | $193.62M | $235.18M | $298.26M | $225.67M | $484.47M | $707.43M | $389.48M |
| Shareholder equity | $1.65B | $1.75B | $1.81B | $1.92B | $1.92B | $1.71B | $1.83B | $1.93B | $1.94B | $1.98B | $2.08B | $1.88B |
Cash Flow
Operating cash flow was negative in the fiscal year ended Dec 2025.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$345.01M | -$142.77M | -$260.38M | -$495.74M | $538.97M | -$238.37M | $56.68M | -$96.24M | -$70.09M | -$52.86M |
| Capital expenditures | $914.00K | $1.90M | $9.47M | $37.19M | $81.70M | $18.36M | $6.68M | $2.77M | $7.81M | $3.02M |
| Free cash flow | -$345.93M | -$144.68M | -$269.85M | -$532.93M | $457.27M | -$256.72M | $49.99M | -$99.01M | -$77.91M | -$55.88M |
| Share repurchases | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $1.81M |
| Investing cash flow | -$31.80M | -$280.48M | $374.65M | -$258.65M | -$1.04B | -$541.17M | $1.32M | -$2.77M | -$8.31M | $31.88M |
| Financing cash flow | $426.03M | $331.98M | $62.66M | $38.59M | $250.94M | $1.02B | $430.98M | $315.93M | $2.61M | $183.22M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$89.68M | -$83.50M | -$108.90M | -$92.55M | -$84.63M | -$113.88M | -$53.95M | -$50.03M | -$106.91M | -$95.58M | $109.75M | -$96.07M |
| Capital expenditures | $414.00K | $648.00K | $504.00K | $517.00K | $74.00K | $117.00K | $206.00K | $254.00K | $219.00K | $707.00K | $721.00K | $738.00K |
| Free cash flow | -$90.10M | -$84.15M | -$109.40M | -$93.07M | -$84.71M | -$114.00M | -$54.15M | -$50.28M | -$107.13M | -$96.29M | $109.03M | -$96.81M |
Frequently Asked Questions About CRSP
What is Crispr Therapeutics AG's annual revenue?
Crispr Therapeutics AG reported revenue of $3.51M for the fiscal year ended Dec 31, 2025.
How fast is Crispr Therapeutics AG's revenue growing?
Revenue was down 90.6% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 43.1%.
Is Crispr Therapeutics AG profitable?
No. Crispr Therapeutics AG reported net income of -$581.60M for the fiscal year ended Dec 31, 2025, with a net margin of -16569.8%.
How much free cash flow does CRSP generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of -$345.01M minus capital expenditures of $914.00K produced free cash flow of -$345.93M.
How much debt does Crispr Therapeutics AG have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $0, short-term debt of $18.58M and cash and equivalents of $347.56M.
CRSP pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors